FDA
-
-
-
-
-
-
-
BrainsWay Reports Cigna’s Evernorth Behavioral Health to Eliminate Prior Authorization Requirements for TMS Coverage, Accelerating Access to Care
-
-
-
-
-
-
-
BrainsWay Announces FDA Approval of Neurolief’s Proliv™Rx Neuromodulation System for Major Depressive Disorder (MDD)
-
-
-
-
-
-
-
BrainsWay Receives FDA Clearance of Deep TMS™ as Adjunct Therapy for Major Depressive Disorder (MDD) in Adolescents Aged 15 to 21
-
-
-
-
-
-
-
BrainsWay Receives FDA Clearance for Accelerated Deep TMS Protocol for Non-Invasive Treatment of Major Depressive Disorder (MDD)
-
-
-
-
-
-
-
BrainsWay Reports Second Quarter 2025 Financial Results and Operational Highlights
-
-
-
-
-
-
-
BrainsWay Reports First Quarter 2025 Financial Results and Operational Highlights
-
-
-
-
-
-
-
BrainsWay Reports Positive Independent Pilot Data on Accelerated Deep TMS Treatment of Alcohol Use Disorder
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

